Global Leaders Pledge $4bn To Tackle Malaria, Others
Global and African leaders including African Heads of State, at the historic Kigali Summit put-up measures to tackle Malaria and Neglected Tropical Diseases’, NTDs by pledging $4 billion.
Hosted by President of the Republic of Rwanda, Paul Kagame, the Kigali Summit featured commitments totaling more than $4 billion including funding from governments, international organizations, philanthropists, and private sector support.
In addition, 18 billion tablets have been donated by pharmaceutical companies for preventing and treating NTDs.
This was the first-ever joint Malaria and NTDs summit with Heads of State hosted on the African continent.
According to the organizers, achieving a healthier and safer world that is free from Malaria and NTDs requires new investments, strategic partnerships across different sectors data-driven and tailored use of current tools and increased investment in disease surveillance and early warning systems
This was the first-ever joint malaria and NTDs summit with Heads of State hosted on the African continent. It was attended by world leaders including His Royal Highness The Prince of Wales, His Excellency Mokgweetsi Masisi, President of the Republic of Botswana, His Excellency Andrew Holness, Prime Minister of Jamaica, the Honourable Dr Philip Isdor Mpango, Vice President of the United Republic of Tanzania, His Excellency Sheikh Shakhboot bin Nahyan Al Nahyan, Minister of State, UAE and the Dr Osagie Ehanire, the Honourable Minister of Health, Federal Republic of Nigeria and took place alongside the Commonwealth Heads of Government Meeting.
In response to the urgent threat of a resurgence in malaria and NTDs made worse by a plateauing of funding, biological challenges and the COVID-19 pandemic, following many years of progress, endemic countries delivered robust pledges at the Summit to demonstrate leadership and action to accelerate progress towards eliminating these diseases by 2030 and galvanise political will.
Malaria and NTD-affected countries committed over $ 2.2 billion in domestic resources toward ending these diseases. These commitments were made in the context of both the Kigali Declaration for NTDs launched on Friday, and a signal of further enhanced domestic resource commitments for malaria at the forthcoming Global Fund replenishment.
Paul Kagame, President of the Republic of Rwanda said: “Ensuring that all African countries mobilise the domestic financial resources required for quality healthcare, is a priority for the African Union, and our partners.
“If there is one thing the pandemic has taught us, it is that together, through coordinated and collaborative action, we can achieve much more.”
Countries called on other global leaders to join them and demonstrate their support by endorsing and committing resources to the Kigali Declaration on NTDs and mobilising at least USD 18 billion for the malaria response at the Global Fund’s Seventh Replenishment Conference in September.
Part of the speech by HRH, The Prince of Wales at a Summit read: “While we have achieved so much in the malaria campaign since 2000, I am afraid that largely due to the Covid-19 pandemic there remains a great amount to do if our ambitions are to be met. I can only hope that today’s meeting signals the necessary focus, and prioritization, of funding for novel therapeutic, prophylactic, and vaccine strategies against malaria.
For example, I understand that the Global Fund to Fight AIDS, Tuberculosis and Malaria reported that 188 million mosquito nets were distributed in 2020 – a seventeen per cent increase compared to 2019, despite Covid-19. And there is a wider hope – we now have more valuable assets at our disposal than ever before. For example, the first W.H.O. approved vaccine, new nets and modern communications tools to monitor our progress and fight against complacency.
It is encouraging to see that leaders of the Commonwealth will discuss and pledge their support for this campaign and are committed to work towards ending the epidemic of malaria by 2030. I very much welcome this determination and that we are not turning our back on a job unfinished.”
The private sector responded to a call from the Heads of Government by stepping up its support too. Private sector organisations made a range of commitments encompassing increased research funding, enhancing local manufacturing capacity including from BioNTech to produce new generation vaccines locally leveraging mRNA technology, support for regional initiatives (such as GoodbyeMalaria), new safe, accessible diagnostics for NTDs such as snakebite envenoming and more than 18 billion tablets were donated to NTDs by nine pharmaceutical companies.
Meanwhile, Pfizer made a ground-breaking commitment to extend its antibiotic donation program through 2030, enabling continued trachoma elimination programs in more than 19 countries globally.
GSK reaffirmed its commitment to donate albendazole until elimination of lymphatic filariasis, extend its soil transmitted helminths (STH) donation to include pre-school children and include a third disease on the WHO’s 2030 NTDs Roadmap, echinococcosis. GSK also committed to invest £1 billion in R&D over the next decade to get ahead of high burden infectious diseases that disproportionately impact LMICs to ensure that no one is left behind.
Novartis is investing USD 250 million to advance R&D into new treatments to combat NTDs and malaria, including USD 100 million to advance R&D of its NTD programme, focusing on novel drug candidates for four diseases, and USD 150 million for next generation antimalarials.
The Wellcome Trust committed to delivering £80 million worth of funding towards research on snakebite envenoming treatment.
Biopharmaceutical company BioNTech announced plans to deliver a highly effective vaccine based on its proprietary mRNA technology for the prevention of malaria and disease-associated mortality, with the clinical trial for the first malaria vaccine candidates to start by the end of 2022.
Further support for malaria and NTDs programmes was also delivered by philanthropic foundations and funds, including the Bill and Melinda Gates Foundation.
Melinda French Gates, Co-Chair, Bill & Melinda Gates Foundation, highlighted the remarkable progress Africans and their partners have made against preventable infectious diseases.
“Over the past two decades, it has been inspiring to see the way leaders have come together to combat malaria and neglected tropical diseases,” said French Gates, who spoke at the Kigali Summit.
“African government officials, health workers, advocates, and scientists have contributed to significant reductions in death and other impacts these diseases have on communities. Tremendous leadership and collaboration with multilateral organizations, donor countries, and pharmaceutical companies are saving lives and helping people live to their fullest potential.”
Progress against malaria and NTDs has stalled in recent years and even reversed in some countries due to a plateauing of funding, rapidly increasing population and widespread insecticide resistance alongside the recent COVID-19 pandemic. This has disrupted health programmes including essential services and supply chains that have put further strain on the fight against malaria.
Dr Tedros Adhanom Ghebreyesus, WHO Director-General, said: “Malaria has afflicted humanity for millennia, but in the past 20 years we have made huge gains, saving many lives. Those gains are now at risk. Without accelerated action, we are in danger of seeing an immediate resurgence of malaria, particularly in Africa. But we have the tools and the strategy to prevent that – and, with new tools, to start to dream of a malaria-free-world.”
Hosted by President of the Republic of Rwanda, Paul Kagame, the Kigali Summit featured commitments totaling more than $4 billion including funding from governments, international organizations, philanthropists, and private sector support.
In addition, 18 billion tablets have been donated by pharmaceutical companies for preventing and treating NTDs.
This was the first-ever joint Malaria and NTDs summit with Heads of State hosted on the African continent.
According to the organizers, achieving a healthier and safer world that is free from Malaria and NTDs requires new investments, strategic partnerships across different sectors data-driven and tailored use of current tools and increased investment in disease surveillance and early warning systems
This was the first-ever joint malaria and NTDs summit with Heads of State hosted on the African continent. It was attended by world leaders including His Royal Highness The Prince of Wales, His Excellency Mokgweetsi Masisi, President of the Republic of Botswana, His Excellency Andrew Holness, Prime Minister of Jamaica, the Honourable Dr Philip Isdor Mpango, Vice President of the United Republic of Tanzania, His Excellency Sheikh Shakhboot bin Nahyan Al Nahyan, Minister of State, UAE and the Dr Osagie Ehanire, the Honourable Minister of Health, Federal Republic of Nigeria and took place alongside the Commonwealth Heads of Government Meeting.
In response to the urgent threat of a resurgence in malaria and NTDs made worse by a plateauing of funding, biological challenges and the COVID-19 pandemic, following many years of progress, endemic countries delivered robust pledges at the Summit to demonstrate leadership and action to accelerate progress towards eliminating these diseases by 2030 and galvanise political will.
Malaria and NTD-affected countries committed over $ 2.2 billion in domestic resources toward ending these diseases. These commitments were made in the context of both the Kigali Declaration for NTDs launched on Friday, and a signal of further enhanced domestic resource commitments for malaria at the forthcoming Global Fund replenishment.
Paul Kagame, President of the Republic of Rwanda said: “Ensuring that all African countries mobilise the domestic financial resources required for quality healthcare, is a priority for the African Union, and our partners.
“If there is one thing the pandemic has taught us, it is that together, through coordinated and collaborative action, we can achieve much more.”
Countries called on other global leaders to join them and demonstrate their support by endorsing and committing resources to the Kigali Declaration on NTDs and mobilising at least USD 18 billion for the malaria response at the Global Fund’s Seventh Replenishment Conference in September.
Part of the speech by HRH, The Prince of Wales at a Summit read: “While we have achieved so much in the malaria campaign since 2000, I am afraid that largely due to the Covid-19 pandemic there remains a great amount to do if our ambitions are to be met. I can only hope that today’s meeting signals the necessary focus, and prioritization, of funding for novel therapeutic, prophylactic, and vaccine strategies against malaria.
For example, I understand that the Global Fund to Fight AIDS, Tuberculosis and Malaria reported that 188 million mosquito nets were distributed in 2020 – a seventeen per cent increase compared to 2019, despite Covid-19. And there is a wider hope – we now have more valuable assets at our disposal than ever before. For example, the first W.H.O. approved vaccine, new nets and modern communications tools to monitor our progress and fight against complacency.
It is encouraging to see that leaders of the Commonwealth will discuss and pledge their support for this campaign and are committed to work towards ending the epidemic of malaria by 2030. I very much welcome this determination and that we are not turning our back on a job unfinished.”
The private sector responded to a call from the Heads of Government by stepping up its support too. Private sector organisations made a range of commitments encompassing increased research funding, enhancing local manufacturing capacity including from BioNTech to produce new generation vaccines locally leveraging mRNA technology, support for regional initiatives (such as GoodbyeMalaria), new safe, accessible diagnostics for NTDs such as snakebite envenoming and more than 18 billion tablets were donated to NTDs by nine pharmaceutical companies.
Meanwhile, Pfizer made a ground-breaking commitment to extend its antibiotic donation program through 2030, enabling continued trachoma elimination programs in more than 19 countries globally.
GSK reaffirmed its commitment to donate albendazole until elimination of lymphatic filariasis, extend its soil transmitted helminths (STH) donation to include pre-school children and include a third disease on the WHO’s 2030 NTDs Roadmap, echinococcosis. GSK also committed to invest £1 billion in R&D over the next decade to get ahead of high burden infectious diseases that disproportionately impact LMICs to ensure that no one is left behind.
Novartis is investing USD 250 million to advance R&D into new treatments to combat NTDs and malaria, including USD 100 million to advance R&D of its NTD programme, focusing on novel drug candidates for four diseases, and USD 150 million for next generation antimalarials.
The Wellcome Trust committed to delivering £80 million worth of funding towards research on snakebite envenoming treatment.
Biopharmaceutical company BioNTech announced plans to deliver a highly effective vaccine based on its proprietary mRNA technology for the prevention of malaria and disease-associated mortality, with the clinical trial for the first malaria vaccine candidates to start by the end of 2022.
Further support for malaria and NTDs programmes was also delivered by philanthropic foundations and funds, including the Bill and Melinda Gates Foundation.
Melinda French Gates, Co-Chair, Bill & Melinda Gates Foundation, highlighted the remarkable progress Africans and their partners have made against preventable infectious diseases.
“Over the past two decades, it has been inspiring to see the way leaders have come together to combat malaria and neglected tropical diseases,” said French Gates, who spoke at the Kigali Summit.
“African government officials, health workers, advocates, and scientists have contributed to significant reductions in death and other impacts these diseases have on communities. Tremendous leadership and collaboration with multilateral organizations, donor countries, and pharmaceutical companies are saving lives and helping people live to their fullest potential.”
Progress against malaria and NTDs has stalled in recent years and even reversed in some countries due to a plateauing of funding, rapidly increasing population and widespread insecticide resistance alongside the recent COVID-19 pandemic. This has disrupted health programmes including essential services and supply chains that have put further strain on the fight against malaria.
Dr Tedros Adhanom Ghebreyesus, WHO Director-General, said: “Malaria has afflicted humanity for millennia, but in the past 20 years we have made huge gains, saving many lives. Those gains are now at risk. Without accelerated action, we are in danger of seeing an immediate resurgence of malaria, particularly in Africa. But we have the tools and the strategy to prevent that – and, with new tools, to start to dream of a malaria-free-world.”
